Taysha Gene Therapies, Inc. (TSHA)
NasdaqGS · USD · Healthcare · Biotechnology
$4.25 (+5.99%) as of
Key statistics
- Market cap
- 1.38B
- Forward P/E
- -9.19
- EPS (TTM)
- -0.4100
- Dividend yield
- 0.00%
- 52-week range
- 3.4550 – 7.3000
- Beta
- 1.17
- Revenue (TTM)
- 5.49M
- Profit margin
- 0.00%
- Analyst target
- $13.00
- Volume
- 2.80M
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Dallas, TX, United States
- Employees
- 99
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.